Abbie R. Bellamy

TL;DR: HSV-1 is now more common than HSV-2 as a cause of oral and genital mucosal infections in young women, but there are important age and race differences.

TL;DR: The primary outcome was safety, measured with occurrence of adverse events for 7 days after vaccination of ChAd3-EBO-Z, and the effect of boosting of Malians with modified vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other filovirus antigens (MVA-BN-Filo).

TL;DR: The vaccine was generally well tolerated, although local and systemic adverse events were significantly more common in the vaccine group, and the efficacy did not reach conventional levels of significance.

TL;DR: Current receipt of seasonal influenza vaccination and older age were associated with attenuated response, and point-of-use mixing and administration of 2 doses of H7N9 vaccine at the lowest tested antigen dose with MF59 adjuvant produced seroconversion in 59% of participants.

TL;DR: The AS03 and MF59 adjuvants augmented the immune responses to 2 doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest titers.